To include your compound in the COVID-19 Resource Center, submit it here.

Friends, Parker Institute call for more flexibility in early T cell therapy development

Friends of Cancer Research and the Parker Institute for Cancer Immunotherapy recommend more flexible IND and manufacturing requirements and the use of adaptive clinical trials to advance development of emerging cellular therapeutics such as CAR T and engineered T cell receptor (TCR) therapies.

In a white paper, the institutions recommended early

Read the full 507 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE